Small interfering RNA (siRNA) has generated enormous interest among both basic and clinical researchers despite the relatively young age of this technology. Theoretically any gene could serve as a target for RNA interference, not just the “druggable” targets against which small-molecule compounds are directed. To develop therapeutics based on siRNA, effective delivery to target tissues and cells is required. However, siRNA cannot cross the cell membrane easily owing to its relatively large size and high negative charge.
No takes yet. Share an insight, caveat, or question.
Liu et al. (2010) studied this question.
Synapse has enriched 5 related papers. Consider them for comparative context: